Le Lézard
Classified in: Health
Subject: RCL

Bayer Issues Voluntary Recall of Alka-Seltzer Plus® Products Due to Labelling Error


WHIPPANY, N.J., March 15, 2018 /PRNewswire/ -- Bayer is voluntarily recalling Alka-Seltzer Plus® packages that:

The affected packages are being recalled because the ingredients on the front sticker may not match the actual product in the carton.

The ingredients listed on the front sticker of the carton may potentially be different from the ingredients listed on the back of the carton. This may lead consumers to ingest a product to which they may have an allergy or anaphylactic reaction, an ingredient which may be contraindicated for their medical condition or they intend to otherwise avoid. There may be potential for serious health consequences. To date, no complaint has been received that resulted in an adverse health consequence.

The Alka-Seltzer Plus products subject to the recall are intended to temporarily relieve symptoms associated with cold and flu, such as cough, congestion, fever and/or mucus.

Bayer is notifying retailers electronically and by certified mail and is arranging for return of all recalled product.

Consumers who purchased packages of Alka-Seltzer Plus that are being recalled should stop using the product and contact Bayer with questions, to report any issues experienced or for instructions about how to receive a refund.

Consumers with questions about this recall can contact Bayer Consumer Relations at:  
1-800-986-0369 (available Monday - Friday 9:00 AM - 5:00 PM ET). Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. 

Consumers may also report adverse reactions or quality problems experienced with the use of this product to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

The recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Contact:

Jennifer Brendel
Bayer U.S.
Email: [email protected]
Office: 862-404-7025
Mobile: 862-246-5028

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 (PRNewsfoto/Bayer)

SOURCE Bayer


These press releases may also interest you

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 11:00
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...

at 11:00
MasterControl, a leading provider of quality management and manufacturing execution software for life sciences, announced it has been recognized by the Imapac 2024 Asia-Pacific Biopharma Excellence Awards in the "Best Bioprocessing Supplier:...

at 10:36
Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been...

at 10:33
The report titled "Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global...



News published on and distributed by: